Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bartoletti

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Urologia Internationalis|April 27, 2000
Focal xanthogranulomatous pyelonephritis with associated bone metaplasiaC Selli, P De Antoni, U Moro, et al.
The Journal of Urology|July 1, 1997
Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidneyC Selli, A Amorosi, G Vona, et al.
Urologia Internationalis|September 26, 2007
Epidemiology and risk factors in urolithiasisR Bartoletti, T Cai, N Mondaini, et al.
Anticancer Research|January 1, 1989
Complete androgen blockade as treatment for advanced prostate cancer: clinical response and side-effectsB Neri, S Bartalucci, A Pieri, et al.
Pathology Oncology Research : POR|October 26, 2018
C-MYC, HIF-1α, ERG, TKT, and GSTP1: an Axis in Prostate Cancer?L Boldrini, R Bartoletti, M Giordano, et al.
Drugs Under Experimental and Clinical Research|January 1, 1989
Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluationT Mazzei, E Mini, M Eandi, et al.
Urology|August 16, 2005
Quality of life after radical treatment of prostate cancer: validation of the Italian version of the University of California-Los Angeles Prostate Cancer IndexM Gacci, L Livi, F Paiar, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 13, 2016
Natural history of human papillomavirus infection in non-vaccinated young males: low clearance probability in high-risk genotypesT Cai, G Perletti, F Meacci, et al.
The Journal of Urology|August 25, 2020
Reply by AuthorsA Pilatz, K Dimitropoulos, R Veeratterapillay, et al.
Anti-Cancer Drugs|December 23, 2004
Weekly paclitaxel and epirubicin in the treatment of symptomatic hormone-refractory advanced prostate carcinoma: report of a phase II trialB Neri, G Cipriani, C Fulignati, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Urologia Internationalis|April 27, 2000
Focal xanthogranulomatous pyelonephritis with associated bone metaplasiaC Selli, P De Antoni, U Moro, et al.
The Journal of Urology|July 1, 1997
Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidneyC Selli, A Amorosi, G Vona, et al.
Urologia Internationalis|September 26, 2007
Epidemiology and risk factors in urolithiasisR Bartoletti, T Cai, N Mondaini, et al.
Anticancer Research|January 1, 1989
Complete androgen blockade as treatment for advanced prostate cancer: clinical response and side-effectsB Neri, S Bartalucci, A Pieri, et al.
Pathology Oncology Research : POR|October 26, 2018
C-MYC, HIF-1α, ERG, TKT, and GSTP1: an Axis in Prostate Cancer?L Boldrini, R Bartoletti, M Giordano, et al.
Drugs Under Experimental and Clinical Research|January 1, 1989
Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluationT Mazzei, E Mini, M Eandi, et al.
Urology|August 16, 2005
Quality of life after radical treatment of prostate cancer: validation of the Italian version of the University of California-Los Angeles Prostate Cancer IndexM Gacci, L Livi, F Paiar, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 13, 2016
Natural history of human papillomavirus infection in non-vaccinated young males: low clearance probability in high-risk genotypesT Cai, G Perletti, F Meacci, et al.
The Journal of Urology|August 25, 2020
Reply by AuthorsA Pilatz, K Dimitropoulos, R Veeratterapillay, et al.
Anti-Cancer Drugs|December 23, 2004
Weekly paclitaxel and epirubicin in the treatment of symptomatic hormone-refractory advanced prostate carcinoma: report of a phase II trialB Neri, G Cipriani, C Fulignati, et al.
Pageof 6